ETTX earnings
Entasis Therapeutics Holdings Inc. (ETTX) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- Entasis Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business UpdateSulbactam-durlobactam (SUL-DUR) achieved all primary and secondary endpoints from landmark Phase 3 ATTACK trialRobust dataset builds compelling case for SUL-DUR which if approved, could become the first, uniquely differentiated and life-saving treatment option for patients with Acinetobacter infectionsPreparing for commercialization ahead of NDA submission in mid-2022, under the leadership of newly appointed Chief Commercial Officer Anna Diaz TriolaEntasis' pathogen-directed platform and latest candidate ETX0462 highlighted by seminal publication in the prestigious scientific journal Nature WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX),
- Entasis Therapeutics to Report Third Quarter 2021 Results and Host Conference Call November 4, 2021WALTHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report third quarter 2021 financial results before the market opens on November 4, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management's prepared remarks. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five min
- Entasis Therapeutics announces positive topline results for sulbactam-durlobactam (SUL-DUR) from Phase 3 ATTACK trialSUL-DUR first to achieve statistical non-inferiority in 28-day all-cause mortality in carbapenem-resistant Acinetobacter (CRAB) patientsStatistically significant difference in clinical cure at Test of Cure vs. colistinFavorable safety profile with statistically significant reduction in nephrotoxicityTargeting NDA submission in mid-2022Management to host a conference call on October 19, 2021, at 8:00am ET WALTHAM, Mass., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced topline results from its ATTACK trial―a global Phase 3 r
- Entasis Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update-Management to Host Conference Call on August 12 at 8am ET- Patient Enrollment in the ATTACK Phase 3 Registrational Trial Completed; Top-Line Data Readout Expected Early Fourth Quarter 2021SUL-DUR Launch Planning Progresses with Appointment of Anna Diaz Triola as Chief Commercial OfficerData On SUL-DUR and ETX0462 Presented at World Microbe Forum $20 Million Private Placement Transaction Completed with Innoviva WALTHAM, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today financial results for the second quarter 2021 an
- Entasis Therapeutics to Report Second Quarter 2021 Results and Host Conference Call August 12, 2021WALTHAM, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that management will report second quarter 2021 financial results before the market opens on August 12, 2021. The company will host a conference call and webcast at 8:00AM Eastern Time to discuss its results and provide a clinical and corporate update. A question-and-answer session will follow management's prepared remarks. Investors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes